• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化类风湿关节炎的甲氨蝶呤治疗:系统文献回顾。

Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review.

机构信息

Service d'immuno-rhumatologie, Lapeyronie Hospital, Montpellier 1 University, Montpellier cedex 5, France.

出版信息

Joint Bone Spine. 2011 Dec;78(6):587-92. doi: 10.1016/j.jbspin.2011.01.010. Epub 2011 Mar 27.

DOI:10.1016/j.jbspin.2011.01.010
PMID:21444233
Abstract

OBJECTIVE

To describe the means of optimizing methotrexate therapy for rheumatoid arthritis in daily clinical practice, based on a systematic literature review.

METHODS

We systematically reviewed the literature by searching the PubMed, Embase, and Cochrane databases and reviewing communications to ACR and EULAR meetings for studies on methotrexate starting dosages, dosage increment sizes and intervals, maximum dosages, and routes of administration in patients with rheumatoid arthritis. We used an appropriate scoring system to assess the methodological quality of each selected study.

RESULTS

We identified 519 studies of which 11 were selected based on the titles and abstracts then on the full-length articles. Methotrexate was optimally effective when started in a high dosage (more than 10mg/week orally) that was subsequently increased by 5mg/month up to 25-30mg/week,(1) with appropriate adjustments based on clinical disease activity and tolerance of each patient. For a given methotrexate dosage, parenteral administration was more effective and produced fewer gastrointestinal adverse effects than oral administration.

CONCLUSION

The information supplied by this systematic review support higher starting dosage, an intensive dosage increase schedule and recourse to parenteral administration in case of unresponsiveness or intolerance to oral methotrexate. They should improve the management of patients given methotrexate therapy for rheumatoid arthritis.

摘要

目的

基于系统文献回顾,描述在日常临床实践中优化甲氨蝶呤治疗类风湿关节炎的方法。

方法

我们通过检索 PubMed、Embase 和 Cochrane 数据库,并回顾 ACR 和 EULAR 会议的交流信息,对甲氨蝶呤起始剂量、剂量递增大小和间隔、最大剂量以及类风湿关节炎患者给药途径的研究进行了系统综述。我们使用适当的评分系统评估了每个入选研究的方法学质量。

结果

我们共确定了 519 项研究,其中 11 项研究是基于标题和摘要,然后是全文入选的。甲氨蝶呤以高剂量(每周超过 10mg 口服)起始,随后每月增加 5mg,最高可达 25-30mg/周时,效果最佳,(1)根据每位患者的临床疾病活动度和耐受性进行适当调整。对于给定的甲氨蝶呤剂量,与口服给药相比,静脉给药更有效,且胃肠道不良反应更少。

结论

本系统综述提供的信息支持更高的起始剂量、更密集的剂量递增方案以及在口服甲氨蝶呤无效或不耐受时采用静脉给药。这些信息应该会改善类风湿关节炎患者接受甲氨蝶呤治疗的管理。

相似文献

1
Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review.优化类风湿关节炎的甲氨蝶呤治疗:系统文献回顾。
Joint Bone Spine. 2011 Dec;78(6):587-92. doi: 10.1016/j.jbspin.2011.01.010. Epub 2011 Mar 27.
2
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
3
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.甲氨蝶呤在类风湿关节炎中的最佳剂量和给药途径:文献系统评价
Ann Rheum Dis. 2009 Jul;68(7):1094-9. doi: 10.1136/ard.2008.092668. Epub 2008 Nov 25.
4
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎:系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
5
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).非甾体抗炎药(包括阿司匹林和对乙酰氨基酚)在接受甲氨蝶呤治疗炎性关节炎(类风湿关节炎、强直性脊柱炎、银屑病关节炎、其他脊柱关节炎)患者中的安全性。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD008872. doi: 10.1002/14651858.CD008872.pub2.
6
Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.英夫利昔单抗与甲氨蝶呤治疗类风湿关节炎:剂量方案的系统评价与荟萃分析
Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007.
7
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.甲氨蝶呤单药治疗以及甲氨蝶呤与传统和生物改善病情抗风湿药物联合治疗类风湿关节炎:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 Aug 29;2016(8):CD010227. doi: 10.1002/14651858.CD010227.pub2.
8
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
9
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
10
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.阿那白滞素治疗成人类风湿关节炎的临床疗效与成本效益:一项系统评价与经济分析
Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180.

引用本文的文献

1
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes.类风湿关节炎的甲氨蝶呤治疗策略:关于剂量和给药途径的范围综述
BMC Rheumatol. 2024 Mar 5;8(1):11. doi: 10.1186/s41927-024-00381-y.
2
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.甲氨蝶呤对阿达木单抗治疗中轴型脊柱关节炎的免疫原性和长期维持效果的影响:一项多中心随机试验。
RMD Open. 2020 Jan;6(1). doi: 10.1136/rmdopen-2019-001047. Epub 2020 Jan 9.
3
Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study.
自动注射器用于甲氨蝶呤皮下自我注射:在SELF-I研究中的高满意度和良好依从性,一项随机、开放标签、平行组研究
Rheumatol Ther. 2019 Mar;6(1):47-60. doi: 10.1007/s40744-018-0134-2. Epub 2018 Dec 13.
4
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].[S2e指南:使用改善病情药物治疗类风湿关节炎]
Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y.
5
Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression.甲氨蝶呤影响类风湿关节炎中高迁移率族蛋白B1(HMGB1)的表达,而HMGB1的下调可阻止类风湿关节炎的进展。
Mol Cell Biochem. 2016 Sep;420(1-2):161-70. doi: 10.1007/s11010-016-2783-1. Epub 2016 Aug 13.
6
Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.甲氨蝶呤与类风湿关节炎:关于皮下注射与口服给药途径的当前证据
Adv Ther. 2016 Mar;33(3):369-78. doi: 10.1007/s12325-016-0295-8. Epub 2016 Feb 4.
7
Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.类风湿关节炎患者中与甲氨蝶呤剂量和给药途径相关的结局:一项系统文献综述
Clin Exp Rheumatol. 2015 Mar-Apr;33(2):272-8. Epub 2014 Dec 23.
8
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.甲氨蝶呤剂量递增联合阿达木单抗的疗效与安全性:随机对照CONCERTO试验
Ann Rheum Dis. 2015 Jun;74(6):1037-44. doi: 10.1136/annrheumdis-2013-204769. Epub 2014 Feb 18.
9
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.类风湿关节炎的生物制剂和口服改善病情抗风湿药物单药治疗。
Ann Rheum Dis. 2013 Dec;72(12):1897-904. doi: 10.1136/annrheumdis-2013-203485. Epub 2013 Aug 5.